Vir’s phase 3 hepatitis delta win fuels push to eclipse Gilead

Vir Biotechnology’s phase 3 trial in chronic hepatitis delta has hit its primary endpoint, giving the biotech the first piece of the package it needs to file for FDA approval next year.